Pharmacogenomics implementation in cardiovascular disease in a highly diverse population: initial findings and lessons learned from a pilot study in United Arab Emirates

Table 4 Genotypes frequencies and a comparison of alternative allele frequency in UAE cohort and gnomAD all populations

Gene	SNP ID	Homozygous Ref	Heterozygous	Homozygous Alt	Alt. Allele freq.¹	GnomAD Alt Allele freq	Chi-square statistic	P-value*
CYP2C19	rs4244285 (2)*	92 (57.5%)	55 (34.4%)	13 (8.1%)	0.253	0.1749	13.54	.00023**
	rs12769205 (2/35)	91 (56.9%)	53 (33.1%)	16 (10%)	0.194	0.1795	16.07	.000061**
	rs4986893 (3)*	153 (95.6%)	7 (4.4%)	0	0.02	0.005	53.98	< .00001**
	rs12248560 (17)*	104 (65%)	48 (30%)	8 (5%)	0.2	0.205	375.41	< .00001**
	rs28399504 (4)*	160 (100%)	0	0	0	0.002	NA	NA
	rs56337013 (5)*	160 (100%)	0	0	0	0.00001	NA	NA
	rs72552267 (7)*	160 (100%)	0	0	0	0.0003	NA	NA
	rs41291556 (8)*	160 (100%)	0	0	0	0.001	NA	NA
VKORC1	rs9923231	66 (41.3%)	59 (36.9%)	38 (21.9%)	0.4	0.32	375.41	< .00001**
CYP2C9	rs1799853 (2)*	142 (88.8%)	13 (8.1%)	5 (3.1%)	0.072	0.09	1.41	.235
	rs1057910 (3)*	94 (58.8%)	64 (40%)	2 (1.3%)	0.213	0.06	125.8	< .00001**
	rs28371686 (5)*	160 (100%)	0	0	0.078	0.001	NA	NA
	rs9332131 (6)*	159 (99.4%)	1 (0.6%)	0	0.003	0.0009	1.534	.215
CYP4F2	rs2108622	80 (50%)	65 (40.6%)	15 (9.4%)	0.297	0.266	1.55	.213
SLCO1B1	rs4149056	110 (68.8%)	46 (28.8%)	4 (2.5%)	0.169	0.133	3.499	.061

Italics indicates significance of Chi-square test
Ref Reference allele, Alt Alternative allele, freq Frequency, NA Testing is not applicable (one of the group counts equals zero)
¹Frequencies of alternative alleles in the current cohort
^* P-value of Chi-square test
^**Significant at P < .01

ISSN: 1479-7364